Cargando…

Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)

BACKGROUND: Aspirin is a key antiplatelet therapy for the prevention of thrombotic events in patients with cardiovascular disease. Studies suggest that ≈20% of patients with cardiac disease suffer from aspirin nonsensitivity, a phenomenon characterized by the inability of 81 mg aspirin to inhibit pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Hamzah, Zamzam, Abdelrahman, Gallant, Reid C., Syed, Muzammil H., Rand, Margaret L., Ni, Heyu, Forbes, Thomas L., Al‐Omran, Mohammed, Qadura, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595963/ https://www.ncbi.nlm.nih.gov/pubmed/34816074 http://dx.doi.org/10.1002/rth2.12618

Ejemplares similares

Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry
por: Khan, Hamzah, et al.
Publicado: (2020)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Plateletworks(®) as a Point-of-Care Test for ASA Non-Sensitivity
por: Khan, Hamzah, et al.
Publicado: (2021)

Formulation of water pollutant discharge limits for malathion based on nonsensitive aquatic organism protection
por: Wei, Yuxia, et al.
Publicado: (2023)

Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy
por: Khan, Hamzah, et al.
Publicado: (2022)

Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients
por: Heidt, Sebastiaan, et al.
Publicado: (2019)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

The In Vivo Granulopoietic Response to Dexamethasone Injection Is Abolished in Perforin-Deficient Mutant Mice and Corrected by Lymphocyte Transfer from Nonsensitized Wild-Type Donors
por: Xavier-Elsas, Pedro, et al.
Publicado: (2015)

De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
por: Cioni, Michela, et al.
Publicado: (2017)

Urinary neutrophil gelatinase-associated lipocalin (NGAL) can potentially predict vascular complications and reliably risk stratify patients with peripheral arterial disease
por: Ehsan, Mehroz, et al.
Publicado: (2022)

Fatty acid binding protein 3 is associated with peripheral arterial disease
por: Syed, Muzammil H., et al.
Publicado: (2020)

MicroRNA Profile of Patients with Chronic Limb-Threatening Ischemia
por: Syed, Muzammil H., et al.
Publicado: (2020)

Aspirin resistance in patients with acute coronary events: risk factors and prevalence as determined by whole blood multiple electrode aggregometry
por: Ibrahim, O., et al.
Publicado: (2013)

Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin
por: Kukula, Krzysztof, et al.
Publicado: (2017)

Fatty Acid Binding Protein 4—A Circulating Protein Associated with Peripheral Arterial Disease in Diabetic Patients
por: Zamzam, Abdelrahman, et al.
Publicado: (2020)

Definition of aspirin resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery: methodological challenges and outcome improvement opportunities
por: Petricevic, M, et al.
Publicado: (2013)

Aspirin for primary stroke prevention in elderly patients with vascular risk factors
por: Uchiyama, Shinichiro
Publicado: (2017)

Platelet aggregometry testing during aspirin or clopidogrel treatment and measurement of clopidogrel metabolite concentrations in dogs with protein‐losing nephropathy
por: Shropshire, Sarah, et al.
Publicado: (2020)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000)

Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y(12 )antagonists by using multiple electrode aggregometry
por: Penz, Sandra M, et al.
Publicado: (2010)

Paroxysmal vascular events in Sturge–Weber syndrome: Role of aspirin
por: Sanghvi, Jyoti, et al.
Publicado: (2014)

Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin
por: Doutremepuich, Christian
Publicado: (2012)

Serum Metabolic Signatures of Chronic Limb-Threatening Ischemia in Patients with Peripheral Artery Disease
por: Azab, Sandi M., et al.
Publicado: (2020)

Impact of Aspirin and Clopidogrel Interruption on Platelet Function in Patients Undergoing Major Vascular Surgery
por: Le Manach, Yannick, et al.
Publicado: (2014)

Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients
por: Cho, AJin, et al.
Publicado: (2019)

Aspirin, a Potential GLUT1 Inhibitor in a Vascular Endothelial Cell Line
por: Hu, Yabo, et al.
Publicado: (2019)

Is there an ideal way to initiate antiplatelet therapy with aspirin? A crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry
por: Meves, Saskia H, et al.
Publicado: (2011)

The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
por: Arfan, Sara, et al.
Publicado: (2022)

Urinary Fatty Acid Binding Protein 3 Has Prognostic Value in Peripheral Artery Disease
por: Li, Ben, et al.
Publicado: (2022)

Urinary Cystatin C Has Prognostic Value in Peripheral Artery Disease
por: Li, Ben, et al.
Publicado: (2022)

Angiogenesis-related proteins as biomarkers for peripheral artery disease
por: Li, Ben, et al.
Publicado: (2023)

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
por: Altman, Raul, et al.
Publicado: (2004)

The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD)()
por: Spies, Jonas Willian, et al.
Publicado: (2015)

Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model
por: Tara, Shuhei, et al.
Publicado: (2015)

Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease
por: Zamzam, Abdelrahman, et al.
Publicado: (2021)

Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease
por: Alsuwailem, Bader, et al.
Publicado: (2021)

The prognostic capability of inflammatory proteins in predicting peripheral artery disease related adverse events
por: Li, Ben, et al.
Publicado: (2022)

Plasma complement component C2: a potential biomarker for predicting abdominal aortic aneurysm related complications
por: Feridooni, Tiam, et al.
Publicado: (2022)

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats
por: Li, Baoshan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6k4slrvt1rv74lq1t4fb4gb56m